Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ARQ 197

Known as: (3R,4R)-3-(5,6-Dihydro-4H-pyrrolo(3,2,1-ij)quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione, ARQ-197, ARQ197 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The hepatocyte growth factor/c-MET pathway has been implicated in the pathobiology of multiple myeloma, and c-MET inhibitors… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2015
2015
MET targeted therapies are under clinical evaluation for non-small-cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Malignant pleural mesothelioma (MPM) is a lethal disease with scarce therapeutic options, and preclinical studies on new targeted… Expand
Is this relevant?
2014
2014
Tivantinib (ARQ197) was first reported as a highly selective inhibitor of c-MET and is currently being investigated in a phase… Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE MET, the high-affinity receptor for hepatocyte growth factor, is frequently deregulated in human cancer. Tivantinib… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
We read with interest the article by Basilico and colleagues ([1][1]), testing the in vitro activity of tivantinib. The article… Expand
Is this relevant?
Review
2011
Review
2011
Hepatocyte growth factor receptor (HGFR), the product of the MET gene, plays an important role in normal cellular function and… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
LBA7502 Background: Orally administered ARQ197 is a selective, non-ATP competitive inhibitor of c-MET (MET), a receptor TK… Expand
Is this relevant?
2010
2010
ARQ-197 is an oral, selective c-Met inhibitor under development by ArQule Inc, in partnership with Daiichi Sankyo Co Ltd and… Expand
Is this relevant?
2009
2009
3549 Background: ARQ197 (A) is a selective, non-ATP competitive inhibitor of c-Met, a receptor tyrosine kinase implicated in… Expand
Is this relevant?